|
| Press Releases |
|
 |
|
| Friday, October 21, 2016 |
|
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
| Tuesday, September 20, 2016 |
|
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
| Wednesday, September 14, 2016 |
|
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
| Thursday, July 7, 2016 |
|
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
| Tuesday, May 31, 2016 |
|
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
| Friday, April 29, 2016 |
|
|
Nanobiotix: 2015 Annual Results |
| Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
| Tuesday, January 5, 2016 |
|
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
| Thursday, July 2, 2015 |
|
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
| Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
| Wednesday, June 10, 2015 |
|
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
エーザイとMerck & Co., Inc、進行腎細胞がん（RCC）患者様を対象とした一次治療としての併用療法を評価する臨床第III相「LITESPARK-012」試験の状況について
Apr 22, 2026 10:40: JST
|
|
|
ソニー・ホンダモビリティの今後の事業の方向性について
Apr 22, 2026 10:10: JST
|
|
|
Seven HKTDC Lifestyle and Licensing mega events to open next week
Apr 22, 2026 09:47 HKT/SGT
|
|
|
A new system to track material design processes
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology 推出 Agentic AI 儲存產品組合，以消除 KV 快取瓶頸
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology 推出 Agentic AI 存储产品组合，旨在消除 KV 缓存瓶颈
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 22, 2026 01:04: JST
|
|
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 21, 2026 22:46 HKT/SGT
|
|
|
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST
|
|
|
New Report Reveals Widespread Misunderstanding of Consumer Messaging App Security Across Government and Critical Infrastructure
Apr 21, 2026 19:00 HKT/SGT
|
|
|
Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST
|
|
|
Global Turbine Asia Advances Aerospace Growth, Capabilities and Talent Development Through Strategic Partnerships
Apr 21, 2026 17:39 HKT/SGT
|
|
|
GMG's Graphene Engine Oil Additive G(R) LUBRICANT: Patent Granted in USA; Allowed in China
Apr 21, 2026 17:07 HKT/SGT
|
|
|
トヨタ、幹部職人事について
Apr 21, 2026 16:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
